GoodRx Holdings, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
GoodRx amended its non-employee director compensation program effective May 27, 2026. Cash compensation includes $50,000 annual board retainer plus additional retainers for committee roles ($10,000–$75,000). Equity compensation provides $200,000 initial RSU award upon appointment and $200,000 annual RSU awards at each stockholder meeting, vesting over one year, with full acceleration upon non-transactional change in control.
Why this rating
Routine governance document clarifying existing director pay structure; no material changes disclosed, standard market practice for public company director comp.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.